Tyra Biosciences, Inc.

NASDAQ:TYRA

Biotechnology

Healthcare
$19.61 -2.48%

-$0.72 today

Market cap
$1.35B
Beta
0.75
P/E (TTM)
-13.4
EPS (TTM)
-$2.12
52W Low $8.98High $40.65

Volume 0.47M

Average 0.96M

TYRA Intangible Assets

Identifiable non-physical assets such as patents, trademarks, licenses, and customer relationships.

Tyra Biosciences, Inc.NASDAQ: TYRA

Intangible Assets · Q1 FY2026 · quarter ended Mar 2026

Intangible assets remains negative

Q1 FY2026 intangible assets was $0, compared with $0 a year earlier.

Context

  • Intangible assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Intangible assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Intangible Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Intangible Assets history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Intangible Assets vs competitors

How TYRA compares with its peers on the latest reported figures

  • TYRA's Mar 2026 intangible assets of $0 is the 3rd highest of the 11 companies compared; the peer median is $0.
  • Intangible assets amounts to 0.0% of total assets for TYRA, versus a peer median of 0.0%.
TYRA Competitors Peer median
Intangible Assets for TYRA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VSTMVerastem, Inc.Mar 2026$16.15M ——7.1%
NUVBNuvation Bio Inc.Jun 2026$10.29M -15.3%—1.4%
TYRATyra Biosciences, Inc.Mar 2026$0 ——0.0%
ORICORIC Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
KURAKura Oncology, Inc.Mar 2026$0 ——0.0%
JANXJanux Therapeutics, Inc.Mar 2026$0 ——0.0%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$0 ——0.0%
CGEMCullinan Therapeutics, Inc.Mar 2026$0 ——0.0%
BCAXBicara Therapeutics Inc. Common StockMar 2026$0 ——0.0%
MGNXMacroGenics, Inc.Mar 2026$0 ——0.0%
FHTXFoghorn Therapeutics Inc.Mar 2026$0 ——0.0%
Peer median (excluding TYRA) $0-15.3%—0.0%

Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents302.18M251.21M58.01M91.97M77.39M
Short-term Investments00145.46M249.48M178.62M
Net Receivables0002M0
Inventory00000
Other Current Assets06.08M8.2M4.02M9.45M
Total Current Assets304.06M257.29M211.67M347.46M265.45M
Property, Plant & Equipment (Net)2.09M3.54M8.15M7.72M6.89M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets555K5.35M6.03M8.38M10.27M
Total Non-current Assets2.64M8.89M14.19M16.1M17.16M
Total Assets306.7M266.18M225.86M363.56M282.61M
Account Payables599K1.15M4.66M590K1.18M
Short-term Debt000412K472K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities005.27M7.14M10.91M
Total Current Liabilities3.62M5.7M15.33M14.59M18.09M
Long-term Debt00005.34M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities367K169K46K3K0
Total Non-current Liabilities1.35M2.65M6.26M5.81M5.34M
Total Liabilities4.96M8.35M21.6M20.41M23.43M
Common Stock4K4K4K5K5K
Retained Earnings(40.37M)(95.7M)(164.83M)(251.31M)(371.26M)
Accumulated OCI00381K770K393K
Other Stockholders Equity00000
Minority Interest00000
Total Equity301.74M257.83M204.26M343.15M259.18M
Total Debt1.18M2.62M6.5M6.22M5.81M
Net Debt(301M)(248.59M)(51.51M)(85.74M)(71.58M)

Tyra Biosciences, Inc.

NASDAQ:TYRA

Intrinsic Alpha fair value

Locked

Current Price

$19.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.